期刊
CURRENT OPINION IN IMMUNOLOGY
卷 47, 期 -, 页码 52-56出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2017.06.010
关键词
-
类别
资金
- National Institutes of Health [AI094417, AI054292, DE021291, AI095113, AI117802, AI059457, OD010850, OD011092, GM065794, HHSN272201100013C, AI100645]
- Bill & Melinda Gates Foundation, Seattle, WA [OPP1108533, OPP1133649]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI059457, UM1AI100645, R37AI054292, R01AI095113, R01AI059457, P01AI094417, R01AI117802, R01AI054292] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE021291] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065794] Funding Source: NIH RePORTER
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U24OD010850, P51OD011092] Funding Source: NIH RePORTER
Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8 + T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据